Antigen binding protein targeting CD40 as well as preparation and application thereof
Patent Information
- Application Number
- CN202380030974.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-08
AI Technical Summary
Existing CD40 antibodies have a problem in clinical application that the therapeutic window between effectiveness and safety is too small, resulting in low objective response rates, significant toxic side effects and low tolerated doses.
Develop an antigen-binding protein targeting CD40 that has high affinity and strong signaling pathway agonistic activity, especially the agonistic activity is enhanced after cross-linking, and contains a specific light chain variable region and a heavy chain variable region, through a specific The amino acid sequence and post-translational modification sites are mutated to form highly efficient antibody molecules.
It significantly improves the patient response rate, expands the treatment window, provides better clinical effects under safe and tolerable dosage conditions, and enhances the binding ability to CD40 and cell activation ability.
Smart Images

Figure CN118922450A_ABST
Abstract
Description
An antigen binding protein targeting CD40 and its preparation and application
[0001] This application claims priority to Chinese patent application No. 2022103511889, filed April 2, 2022. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field
[0002] The present invention relates to the field of biopharmaceuticals, and in particular to an antigen binding protein targeting CD40 and its preparation and application. Background Art
[0003] CD40 is a glycosylated type I transmembrane protein and a member of the tumor necrosis factor receptor superfamily (TNFRSF), also known as tumor necrosis factor receptor superfamily member 5 (TNFRSF5). CD40 is expressed on the surface of a range of antigen-presenting cells (APCs), including monocytes, dendritic cells (DCs), B cells, and macrophages. Its ligand, CD40L, is primarily expressed on the surface of lymphocytes, including T cells, B cells, and natural killer (NK) cells, typically existing in trimer and multimer forms. CD40 and CD40L are a pair of co-stimulatory molecules. Activation of CD40 downstream signaling pathways requires cross-linking of CD40 by trimers and multimers of CD40L. They interact on the cell surface, causing CD40 to redistribute to membrane lipid rafts and undergo conformational changes. CD40 recruits TNFR-associated factors (TRAFs) in the cytoplasm through its intracellular terminal domain to promote intracellular signal transduction, thereby activating different signaling pathways, such as the canonical and non-canonical nuclear factor κB pathways, p38 mitogen-activated protein kinase, phosphatidylinositol-3 kinase (PI3K), and phospholipase Cγ pathways. Through the genes targeted by these signaling pathways, they further regulate cell apoptosis, cell cycle progression, cytokine production, and the expression of cell surface immune regulators. Therefore, activating CD40 can increase antigen presentation, promote cytokine secretion, activate lymphocytes, and simultaneously stimulate and activate the human innate and adaptive immune systems, producing a synergistic effect to resist the occurrence and development of cancer.
[0004] CD40 is also widely expressed on tumor cells. It is expressed in nearly all B-cell malignancies and a wide range of solid tumors, including melanoma, lung cancer, breast cancer, colon cancer, prostate cancer, pancreatic cancer, kidney cancer, ovarian cancer, and head and neck cancer. CD40 expressed on the surface of tumor cells can mediate tumor cell death. In the absence of immune helper cells, cross-linking CD40 expressed on the surface of various tumor cells through CD40L can mediate direct cytotoxicity. In vitro, cross-linking of CD40 through CD40L has been shown to induce tumor cell apoptosis and inhibit the growth of solid tumor cells and B-cell malignancies. In vivo, activation of CD40 also mediates tumor suppression. Evidence shows that in immunodeficient mice, interfering with CD40 on the surface of tumor cells through CD40L inhibits the growth of breast cancer cell xenografts or B lymphocyte xenografts, even in the absence of lymphocyte activation.
[0005] Therefore, the mechanism of CD40-mediated tumor cell death can be dual: stimulating the immune system to kill tumor cells and directly cytotoxic to tumor cells, resulting in a synergistic anti-tumor effect. Agonistic anti-CD40 antibodies, similar to CD40L, can cross-link and activate CD40 on the surface of immune cells and tumor cells, exerting a significant anti-tumor effect. This anti-tumor effect has been demonstrated in preclinical animal models and clinical cancer patient trials, and can be combined with chemotherapy drugs such as gemcitabine and paclitaxel, as well as with immunomodulatory drugs such as PD-1 and CTLA-4 antibodies, to produce a synergistic anti-tumor effect.
[0006] Currently, there are over 20 CD40 antibody drugs in clinical trials, but the earliest products are only in Phase II clinical trials, and no products have yet been marketed. Therefore, the development of other CD40 antibodies will provide potential treatments for a variety of tumors and immune system-related diseases, and has high market value.
[0007] In the anti-tumor field, the main challenges faced by CD40 antibodies in clinical practice include low objective response rates, significant toxic side effects, and low tolerable doses. These results may be due to weak agonist activity, such as Celldex's product CDX-1140. In its Phase I clinical trial, no complete or partial responses were seen in 42 patients treated with monotherapy; in combination with rhFLT3L, only one of 20 patients achieved a partial response. This product exhibited weak activation of DCs in vitro, and its agonist activity was not enhanced when cross-linked. In clinical trials, Roche's CD40 antibody Selicrelumab caused significant cytokine release syndrome and liver toxicity in some patients at doses exceeding 0.2 mg / kg. In clinical trials, Apexigen's CD40 antibody APX005M caused significant neutropenia, as well as further sepsis and septic shock, in some patients at doses exceeding 0.3 mg / kg. In addition, the human-mouse chimeric sequence CD40 monoclonal antibody ChiLob7 / 4 failed due to the human anti-chimeric antibody effect (HACA) in a phase I clinical trial. In summary, the current clinical CD40 antibodies face the problem and challenge of a narrow therapeutic window between effectiveness and safety.
[0008] Summary of the Invention
[0009] To address the technical limitations of existing CD40 antibodies, which suffer from a narrow therapeutic window between effectiveness and safety, the present invention provides a CD40-targeting antigen-binding protein, its preparation, and use. This CD40-targeting antigen-binding protein exhibits high affinity for CD40 and strong agonistic activity on signaling pathways, particularly enhanced after cross-linking. This allows for a wider therapeutic window and improved safety, potentially opening new opportunities for the treatment of various tumors.
[0010] To solve the above technical problems, the present invention provides a technical solution: an antigen-binding protein targeting CD40, wherein the antigen-binding protein comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3, and the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3; wherein:
[0011] The LCDR1 includes the amino acid sequence as shown in SEQ ID NO:33, or variant 1 having 3, 2 or 1 amino acid mutations in SEQ ID NO:33, the LCDR2 includes the amino acid sequence as shown in SEQ ID NO:41, or variant 2 having 3, 2 or 1 amino acid mutations in SEQ ID NO:41, and the LCDR3 includes the amino acid sequence as shown in SEQ ID NO:49, or variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:49; the HCDR1 includes the amino acid sequence as shown in SEQ ID NO:7, or variant 4 having 3, 2 or 1 amino acid mutations in SEQ ID NO:7, the HCDR2 includes the amino acid sequence as shown in SEQ ID NO:15, or variant 5 having 3, 2 or 1 amino acid mutations in SEQ ID NO:15, and the HCDR3 includes the amino acid sequence as shown in SEQ ID NO:23, or variant 6 having 3, 2 or 1 amino acid mutations in SEQ ID NO:23.
[0012] Preferably, the variant 3 includes an amino acid sequence having a PTM site mutation in the amino acid sequence shown in SEQ ID NO: 49, preferably including an amino acid sequence having an amino acid mutation at position 4 and / or 5 of the amino acid sequence shown in SEQ ID NO: 49, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution.
[0013] In some technical solutions of the present invention, the variant 3 is an amino acid sequence as shown in any one of SEQ ID NOs: 50-73.
[0014] In some technical solutions of the present invention, the LCDR1 includes the amino acid sequence shown in SEQ ID NO:33, the LCDR2 includes the amino acid sequence shown in SEQ ID NO:41, and the LCDR3 includes the amino acid sequence shown in any one of SEQ ID NOs:49-73; the HCDR1 includes the amino acid sequence shown in SEQ ID NO:7, the HCDR2 includes the amino acid sequence shown in SEQ ID NO:15, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO:23. The specific CDR combinations are shown in Table 1-1 below.
[0015] Table 1-1: Specific CDR combinations
[0016] Preferably, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 85, and the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 81. More preferably, the light chain variable region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 85-109, and the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81. Specific combinations of light chain variable regions and heavy chain variable regions are shown in Tables 1-2 below.
[0017] Table 1-2: Specific light chain variable region and heavy chain variable region combinations
[0018] Preferably, the antigen binding protein targeting CD40 satisfies at least one of the following three conditions:
[0019] (1) The antigen-binding protein targeting CD40 is a full-length antibody, Fab, Fab', F(ab')2 or Fv, and the Fv is preferably a scFv;
[0020] (2) The antigen-binding protein targeting CD40 is a monospecific antibody, a bispecific antibody, or a multispecific antibody;
[0021] (3) The antigen binding protein targeting CD40 is a monoclonal antibody or a polyclonal antibody.
[0022] Preferably, the antigen binding protein targeting CD40 is a full-length antibody, which comprises a light chain and a heavy chain; the light chain includes a light chain constant region (CL), which is preferably a human antibody light chain constant region; the heavy chain includes a heavy chain constant region (CH), which is preferably a human antibody heavy chain constant region, more preferably a heavy chain constant region of the hIgG1, hIgG2, hIgG3 or hIgG4 subtype, and further preferably a heavy chain constant region of the hIgG1 subtype.
[0023] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 114 or 115, and the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 119-143. Preferably, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 114, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 119; or, the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 115, and the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 119-143. Specific light and heavy chain combinations are shown in Tables 1-3 below.
[0024] Table 1-3: Specific light chain and heavy chain combinations
[0025] In the present invention, the numbers in variant 1, variant 2, variant 3, variant 4, variant 5 and variant 6 are only used to distinguish different variants and do not represent actual meanings.
[0026] In the present invention, the PTM site is a site where chemical modifications are sometimes introduced into the protein or polypeptide amino acid chain after translation and synthesis in cells, and is called a post-translational modification (PTM) site.
[0027] The amino acid sequences of the CDRs in the present invention are determined according to the Chothia definition rules.
[0028] To solve the above technical problems, the present invention provides another technical solution: a chimeric antigen receptor (CAR), which comprises the CD40-targeting antigen binding protein as described in the present invention.
[0029] To solve the above technical problems, the present invention provides another technical solution: an isolated nucleic acid encoding the antigen binding protein targeting CD40 as described in the present invention or the chimeric antigen receptor as described in the present invention.
[0030] To solve the above technical problems, the present invention provides another technical solution: a recombinant expression vector comprising the isolated nucleic acid as described in the present invention. Preferably, the recombinant expression vector comprises a eukaryotic expression vector and / or a prokaryotic expression vector.
[0031] To solve the above technical problems, the present invention provides another technical solution: a transformant comprising the isolated nucleic acid or the recombinant expression vector described herein. Preferably, the host cell of the transformant is a prokaryotic cell and / or a eukaryotic cell, the prokaryotic cell preferably being an E. coli cell such as TG1 or BL21, and the eukaryotic cell preferably being an HEK293 cell or a CHO cell.
[0032] To solve the above technical problems, the present invention provides another technical solution: a method for preparing the antigen-binding protein targeting CD40 as described in the present invention, comprising the following steps: culturing the transformant as described in the present invention, and obtaining the antigen-binding protein targeting CD40 from the culture.
[0033] To address the above technical issues, the present invention provides another technical solution: an antibody-drug conjugate (ADC) comprising the CD40-targeting antigen binding protein described herein and a cytotoxic agent or a tag. Preferably, the cytotoxic agent is MMAF or MMAE, and the tag is a fluorescent agent.
[0034] To address the above technical issues, the present invention provides another technical solution: a genetically modified cell that expresses the chimeric antigen receptor described in the present invention. Preferably, the genetically modified cell is a eukaryotic cell, preferably an isolated human cell, and more preferably an immune cell such as a T cell or a NK cell.
[0035] To address the above technical problems, the present invention provides another technical solution: a pharmaceutical composition comprising the CD40-targeting antigen-binding protein described herein, the isolated nucleic acid described herein, the recombinant expression vector described herein, the genetically modified cell described herein, and / or the antibody-drug conjugate described herein, as well as a pharmaceutically acceptable carrier and / or a pharmaceutically acceptable adjuvant. Preferably, the pharmaceutical composition also includes another anti-tumor antibody as an active ingredient.
[0036] To address the above technical problems, the present invention provides another technical solution: a detection reagent comprising the CD40-targeting antigen-binding protein and / or the antibody-drug conjugate described herein. Preferably, the detection reagent is in liquid, gaseous, solid, or semisolid dosage form. More preferably, the detection reagent further comprises a secondary antibody, CD40, or a derivative thereof, such as an anti-human IgG antibody conjugated to horseradish peroxidase and an anti-human IgG antibody conjugated to biotin.
[0037] To solve the above technical problems, the present invention provides another technical solution: a kit comprising a kit A, wherein the kit A contains one or more of the antigen-binding protein targeting CD40 as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the genetically modified cells as described in the present invention, and the antibody-drug conjugate as described in the present invention.
[0038] Preferably, the kit further comprises a kit B, which contains other anti-tumor antibodies or pharmaceutical compositions comprising the other anti-tumor antibodies, and / or one or more of a group consisting of hormone preparations, targeted small molecule preparations, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, and vaccines.
[0039] To solve the above technical problems, another technical solution provided by the present invention is: the use of one or more of the antigen binding protein targeting CD40 as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the kit as described in the present invention, the genetically modified cell as described in the present invention, and the antibody-drug conjugate as described in the present invention in the preparation of a drug for diagnosing, preventing and / or treating diseases such as tumors. Preferably, the tumor includes solid tumors and hematological tumors. More preferably, the tumor includes B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer.
[0040] To address the above technical problems, the present invention provides another technical solution: a method for detecting CD40 in a sample, comprising contacting the sample with one or more of the CD40-targeting antigen-binding protein described herein, the detection reagent described herein, and the antibody-drug conjugate described herein. The sample, for example, is a blood sample (e.g., a whole blood sample or a serum sample) and a reagent containing CD40. Preferably, the method is for non-diagnostic and / or therapeutic purposes, such as detecting the concentration of a CD40 standard or determining whether other reagents are contaminated with CD40 in scientific research.
[0041] To solve the above technical problems, another technical solution provided by the present invention is: a method for diagnosing, treating and / or preventing tumors, the method comprising administering to a patient in need thereof a therapeutically effective amount of one or more of the antigen-binding protein targeting CD40 as described in the present invention, the isolated nucleic acid as described in the present invention, the recombinant expression vector as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the genetically modified cell as described in the present invention, and the antibody-drug conjugate as described in the present invention, or using the kit as described in the present invention to diagnose or treat a patient in need thereof. Preferably, the tumor includes solid tumors and hematological tumors. More preferably, the tumor includes B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer, and colon cancer.
[0042] To solve the above technical problems, another technical solution provided by the present invention is: the use of one or more of the antigen-binding protein targeting CD40 as described in the present invention, the isolated nucleic acid as described in the present invention, the recombinant expression vector as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the kit as described in the present invention, the genetically modified cell as described in the present invention, and / or the antibody-drug conjugate as described in the present invention in the preparation of a drug for diagnosing, preventing or treating tumors. Preferably, the tumor includes solid tumors and hematological tumors. More preferably, the tumor includes B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal carcinoma, malignant melanoma, pancreatic cancer and colon cancer.
[0043] In the present invention, "having 3, 2, or 1 amino acid mutations" refers to insertions, deletions, or substitutions of amino acids in the original amino acid sequence. Exemplary explanations include CDR mutations that include 3, 2, or 1 amino acid mutations. Mutations in these CDRs can optionally involve the same or different numbers of amino acid residues. For example, a single amino acid mutation can be made in CDR1, while no amino acid mutations can be made in CDR2 or CDR3.
[0044] In the present invention, "PTM site mutation" refers to a mutation of the amino acid at the PTM site in the sequence of the variant compared to the original amino acid sequence. Depending on the difference between the antibody sequence and the PTM sequence pattern, there are different mutation design methods. One method is to replace the "hot spot" amino acid (such as N or S in the NS pattern) with an amino acid with similar physicochemical properties (such as mutating N to Q). If the PTM sequence pattern comes from a somatic high-frequency mutation and is not present in the germline gene sequence, then another method can be to replace the sequence pattern with the corresponding germline gene sequence.
[0045] In the present invention, the VH, VL, or full-length antibody may include mutations based on the defined sequences. The mutation is a deletion, substitution, or addition of one or more amino acid residues to the defined amino acid sequence, and the mutated amino acid sequence has at least 85% sequence identity with the defined amino acid sequence and maintains or improves the binding activity of the antigen-binding protein containing the mutated amino acid sequence; the at least 85% sequence identity is preferably at least 90% sequence identity; more preferably at least 95% sequence identity; and most preferably at least 99% sequence identity.
[0046] In the present invention, “including”, “comprising” and “for” have the same meaning in certain specific embodiments.
[0047] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0048] The reagents and raw materials used in the present invention are commercially available.
[0049] The positive progress effect of the present invention is:
[0050] The antigen binding protein targeting CD40 has the characteristics of high affinity for CD40 and strong agonistic activity on signaling pathways, especially enhanced agonistic activity after cross-linking, which makes the antigen binding protein targeting CD40 of the present invention have a larger therapeutic window, providing a good basis for significantly improving patient response rates under safe and tolerable dosage conditions in clinical trials. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] FIG1A , FIG1B , FIG1C , and FIG1D respectively show the levels of binding of some CD40 antibodies to CHO-K1 cells that highly express human CD40.
[0052] FIG2A , FIG2B , FIG2C , FIG2D , and FIG2E respectively show the levels of binding of some CD40 antibodies to Raji cells that highly express human CD40.
[0053] FIG3A , FIG3B , FIG3C , and FIG3D respectively show the levels of binding of some CD40 antibodies to CHO-K1 cells that highly express cynomolgus monkey CD40.
[0054] Figures 4A, 4B, 4C, and 4D respectively show the levels of activation of HEK293-hCD40-NFkB fluorescent reporter cells by the tested CD40 antibody PR003379 and three control antibodies with or without CHO-K1 / hCD32B cell-mediated cross-linking.
[0055] Figure 5A shows the fluorescence intensity enhancement fold of the variant molecules of the CD40 antibody PR003379 in the presence of CHO-K1 / hCD32B cell-mediated cross-linking on HEK293-hCD40-NFkB cells. Figure 5B shows the fluorescence intensity enhancement fold of the variant molecules of the CD40 antibody PR003379 in the absence of CHO-K1 / hCD32B cell-mediated cross-linking on HEK293-hCD40-NFkB cells.
[0056] Figures 6A, 6B, 6C and 6D respectively show the activation effects (IL12p40 release levels) of the tested CD40 antibody PR003379 and three control antibodies on human DC cells with or without CHO-K1 / hCD32B cell-mediated cross-linking.
[0057] FIG7 shows the level of inhibition of CD40 and CD40L binding by CD40 antibodies.
[0058] Figure 8A shows the changes in tumor volume as a function of the anti-tumor effect of CD40 antibody in the MC38-hPD-L1 / CD40 humanized mouse model, and Figure 8B shows the changes in mouse weight as a function of the anti-tumor effect of CD40 antibody in the MC38-hPD-L1 / CD40 humanized mouse model. DETAILED DESCRIPTION
[0059] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0060] In this application, the term "binding protein" or "antigen binding protein" generally refers to a protein comprising a portion that binds to an antigen, and optionally a scaffold or backbone portion that allows the portion that binds to the antigen to adopt a conformation that promotes binding of the antigen binding protein to the antigen. It may typically comprise an antibody light chain variable region (VL), an antibody heavy chain variable region (VH), or both. The VH and VL regions can be further divided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs). Each VH and VL can be composed of three CDRs and four FR regions, which can be arranged in the following order from amino terminus to carboxyl terminus: FR-1, CDR1, FR-2, CDR2, FR-3, CDR3, and FR-4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The three CDRs of VH are represented as HCDR1, HCDR2, and HCDR3, respectively, and may also be represented as VH CDR1, VH CDR2, and VH CDR3; the three CDRs of VL are represented as LCDR1, LCDR2, and LCDR3, respectively, and may also be represented as VL CDR1, VL CDR2, and VL CDR3. Examples of antigen-binding proteins include, but are not limited to, antibodies, antigen-binding fragments (Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, and / or dAb), immunoconjugates, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, antibody derivatives, antibody analogs, or fusion proteins, as long as they exhibit the desired antigen-binding activity.
[0061] In the present application, the amino acid sequence of the CDR is shown in accordance with the Chothia definition rule. However, it is well known to those skilled in the art that the CDR of an antibody can be defined in this area by a variety of methods, such as the Kabat definition rule based on sequence variability (see, Kabat et al., Protein Sequences in Immunology, 5th edition, National Institutes of Health, Bethesda, Maryland (1991)) and the Chothia definition rule based on the structural loop region position (see J Mol Biol 273:927-48,1997). In the technical scheme of the present invention, the Combined definition rule comprising the Kabat definition and the Chothia definition can also be used to determine the amino acid residues in the variable domain sequence. Wherein the Combined definition rule is to combine the scope of the Kabat definition and the Chothia definition, and a larger scope is taken based on this, see Table 1-4 below for details. It will be understood by those skilled in the art that, unless otherwise specified, the term "CDR" and "complementary determining region" of a given antibody or its district (such as variable region) should be understood to encompass the complementary determining region defined in any one of the above-mentioned known schemes described by the present invention. Although the scope of protection claimed in the present invention is based on the sequence shown in the Chothia definition rules, the amino acid sequences corresponding to other CDR definition rules should also fall within the scope of protection of the present invention.
[0062] Table 1-4: Antibody CDR definition method in this application
[0063] Among them, Laa-Lbb can refer to the amino acid sequence starting from the N-terminus of the antibody light chain, from position aa (Chothia numbering rules) to position bb (Chothia numbering rules); Haa-Hbb can refer to the amino acid sequence starting from the N-terminus of the antibody heavy chain, from position aa (Chothia numbering rules) to position bb (Chothia numbering rules). For example, L24-L34 can refer to the amino acid sequence starting from the N-terminus of the antibody light chain, from position 24 to position 34 according to the Chothia numbering rules; H26-H32 can refer to the amino acid sequence starting from the N-terminus of the antibody heavy chain, from position 26 to position 32 according to the Chothia numbering rules. It should be known to those skilled in the art that when using Chothia to encode CDRs, some positions may have insertion sites (see http: / / bioinf.org.uk / abs / ).
[0064] In this application, the term "monoclonal antibody" generally refers to the antibody obtained from a group of substantially homogeneous antibodies, i.e., the individual antibodies in the cluster are identical, except for a small amount of natural mutations that may exist. Monoclonal antibodies are generally highly specific for a single antigenic site. And, different from conventional polyclonal antibody preparations (generally having different antibodies for different determinants), each monoclonal antibody is for a single determinant on the antigen. Except for their specificity, the advantage of monoclonal antibodies is that they can be synthesized by hybridoma culture, and are not polluted by other immunoglobulins. The modifier "monoclonal" represents the feature of the antibody obtained from a substantially homogeneous antibody colony, and is not interpreted as needing to produce antibody by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared in hybridoma cell, or can be prepared by recombinant DNA method.
[0065] In this application, the term "fully human antibody" generally refers to antibodies expressed by animals that have transferred all human antibody-encoding genes into genetically engineered antibody gene-deficient animals. All parts of the antibody (including the variable and constant regions of the antibody) are encoded by genes of human origin. Fully human antibodies can greatly reduce the immune side effects caused by heterologous antibodies to the human body. Methods for obtaining fully human antibodies in this field include phage display technology, transgenic mouse technology, etc.
[0066] In this application, the terms "specific binding" and "targeting" generally refer to the binding of an antibody to an epitope through its antigen binding domain, and that this binding requires some complementarity between the antigen binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an antigen when it is more likely to bind to an epitope through its antigen binding domain than it would bind to a random, unrelated epitope. "Epitope" refers to a specific group of atoms (e.g., sugar side chains, phosphoryl groups, sulfonyl groups) or amino acids on an antigen to which an antigen-binding protein (such as an antibody) binds.
[0067] In this application, the term "Fab" generally refers to the antigen-binding portion of a conventional antibody (e.g., IgG), comprising the antibody's heavy chain variable region VH, light chain variable region VL, heavy chain constant region domain CHI, and light chain constant region CL. In conventional antibodies, the C-terminus of VH is linked to the N-terminus of CHI to form the heavy chain Fd fragment, the C-terminus of VL is linked to the N-terminus of CL to form the light chain, and the C-terminus of CHI is further linked to the hinge region and other constant region domains of the heavy chain to form the heavy chain. In some embodiments, "Fab" also refers to variant structures of Fab. For example, in certain embodiments, the C-terminus of VH is linked to the N-terminus of CL to form one polypeptide chain, and the C-terminus of VL is linked to the N-terminus of CHI to form another polypeptide chain, forming a Fab (cross VH / VL) structure. In certain embodiments, the CHI of Fab is not linked to the hinge region, but the C-terminus of CL is linked to the hinge region of the heavy chain, forming a Fab (cross Fd / LC) structure.
[0068] In this application, the term "VH" generally refers to the heavy chain variable region VH domain of an antibody, that is, it can be the heavy chain variable region VH of a conventional antibody (H2L2 structure) of humans or other animals, or the heavy chain variable region VHH of a heavy chain antibody (HCAb structure) of animals such as camelids, or the heavy chain variable region VH of a fully human heavy chain antibody (HCAb structure) produced using Harbour HCAb transgenic mice.
[0069] In this application, the term "CD40" generally refers to the tumor necrosis factor receptor superfamily member 5 protein, its functional variants, and / or functional fragments thereof, also known as TNFRSF5. CD40 sequences are known in the art. For example, an exemplary amino acid sequence of human CD40 protein can be found under UniProt Accession No. P25942; an exemplary cynomolgus monkey CD40 protein sequence can be found under UniProt Accession No. G7PG38; and an exemplary mouse CD40 protein sequence can be found under UniProt Accession No. P27512. CD40L is the natural trimeric ligand molecule for CD40.
[0070] Example
[0071] The present invention is further illustrated by way of examples, which are not intended to limit the invention to the scope of these examples. The examples do not include detailed descriptions of conventional methods, such as those used to construct vectors and plasmids, insert protein-encoding genes into such vectors and plasmids, or introduce plasmids into host cells. Such methods are well known to those skilled in the art and are described in numerous publications. Experimental procedures in the following examples, where specific conditions are not specified, were performed according to conventional methods and conditions or as selected from commercially available product specifications.
[0072] Example 1 Preparation of CD40 Antibody
[0073] Advances in transgenic technology have enabled the creation of genetically engineered mice that carry a human immunoglobulin repertoire and lack the endogenous mouse immune repertoire. The antibodies produced by these transgenic mice possess fully human sequences, eliminating the need for further humanization and significantly improving the efficiency of therapeutic antibody development. Harbour H2L2 mice (Harbour Antibodies BV) are transgenic mice that carry a human immunoglobulin repertoire and produce antibodies with fully human variable domains and rat constant domains.
[0074] Harbour H2L2 mice were immunized multiple times with a soluble recombinant human CD40 extracellular domain fusion protein (Acrobiosystems, #CD0-H5253). The antigen protein was mixed with an immune adjuvant to form an immunogen, which was then injected subcutaneously into the inguinal cavity or intraperitoneally. In each round of immunization, each mouse received a total injection dose of 100 μL. In the first round of immunization, each mouse received an immunogen prepared by mixing 50 μg of the antigen protein with complete Freund's adjuvant (Sigma, #F5881) at a 1:1 volume ratio. In each subsequent booster round, each mouse received an immunogen prepared by mixing 25 μg of the antigen protein with Sigma Adjuvant System adjuvant (Sigma, #S6322). Each booster round was separated by at least two weeks, and typically did not exceed five rounds. Immunizations were performed on days 0, 14, 28, 42, 56, and 70, and serum antibody titers were measured on days 49 and 77. Three days before cell fusion, a final booster immunization was performed with 25 μg of antigen protein per mouse.
[0075] After the CD40-specific antibody titer in mouse serum reached a certain level, the mouse spleen cells were removed and fused with a myeloma cell line to generate hybridoma cells. After multiple rounds of screening and cloning, hybridomas expressing CD40 monoclonal antibody molecules were isolated. The isolated hybridomas expressed antibody molecules with complete human variable domains and rat constant domains for both heavy and light chains. These monoclonal antibodies were further characterized, and several hybridoma clones were selected for sequencing based on parameters such as their binding ability to human CD40, cynomolgus monkey CD40, and their ability to activate CD40 downstream signaling pathways. During the screening process, the positive control antibodies listed in Tables 1-5 were used (see Table 4 for corresponding sequence numbers). The nucleotide sequences encoding the variable domains of the antibody molecules and the corresponding amino acid sequences were obtained using conventional hybridoma sequencing methods. In this example, the variable domain sequences of the CD40 monoclonal antibody molecules obtained from immunized Harbour H2L2 mice were human antibody sequences. The CDR sequences of the antibody variable domain can be analyzed using Kabat, Chothia, or other CDR definition rules (Tables 1-5).
[0076] Table 1-5: CD40 positive control antibodies
[0077] After obtaining the light and heavy chain variable domain sequences encoding the antibody molecules, conventional recombinant DNA technology can be used to fuse the light and heavy chain variable domain sequences and the corresponding human antibody light and heavy chain constant domain sequences to obtain recombinant antibody molecules. In this embodiment, the antibody heavy chain variable domain sequence (VH) is synthesized by gene synthesis and cloned into a mammalian cell expression plasmid vector encoding the human IgG2 antibody heavy chain constant domain sequence to encode the full-length heavy chain of the IgG2 antibody. The antibody light chain variable domain sequence (VL) is synthesized by gene synthesis and cloned into a mammalian cell expression plasmid vector encoding the human antibody Igκ light chain constant domain sequence to encode the full-length light chain of the antibody. In this embodiment, a fully human anti-CD40 recombinant IgG2 antibody is obtained.
[0078] PR006239 was synthesized by linking the nucleic acid encoding the heavy chain variable region (VH) of PR003379 to a nucleic acid encoding the heavy chain constant domain sequence of an IgG1 subtype antibody containing the L234A, L235A, and G237A mutations. The nucleic acid was then cloned into a mammalian cell expression plasmid to encode the full-length IgG1 (L234A, L235A, G237A) heavy chain. The nucleic acid encoding the light chain variable domain sequence (VL) of the antibody was synthesized and cloned into a mammalian cell expression plasmid vector encoding the human Igκ light chain constant domain sequence to encode the full-length light chain of the antibody. The two plasmids were co-transfected into mammalian cells for expression, production, and purification to produce the fully human anti-CD40 recombinant IgG1 (L234A, L235A, G237A) antibody PR006239. For detailed antibody expression and purification methods, see Example 2.
[0079] Example 2 Transient transfection expression and purification of antibodies
[0080] This example describes a general method for producing antibodies using mammalian host cells (e.g., human embryonic kidney (HEK293) cells or Chinese hamster ovary (CHO) cells and their derivatives), transient transfection expression, and affinity capture isolation. This method is applicable to target antibodies containing an Fc region; the target antibody can be composed of one or more protein polypeptide chains and can be derived from one or more expression plasmids.
[0081] The amino acid sequence of the antibody polypeptide chain is converted into a nucleotide sequence through codon optimization methods; the encoding nucleotide sequence is synthesized and cloned into an expression vector compatible with the host cell. The plasmids encoding the antibody polypeptide chain are simultaneously transfected into mammalian host cells at a specific ratio, and conventional recombinant protein expression and purification techniques are used to obtain recombinant antibodies with correct folding and polypeptide chain assembly. Specifically, FreeStyle TM 293-F cells (Thermo, #R79007) were cultured in FreeStyle TM Before transient transfection, adjust the cell density to 6–8×10 5 cells / ml, and cultured in a shaker at 37°C with 8% CO2 for 24 hours. The cell concentration was 1.2×10 6Cells / ml. Prepare 30ml of cultured cells. The plasmid encoding the antibody polypeptide chain (pTT5, NRC) was mixed in a certain proportion, and a total of 30μg of plasmid (the ratio of plasmid to cells was 1μg:1ml) was dissolved in 1.5ml of Opti-MEM reduced serum medium (Thermo, #31985088), and sterilized by filtration with a 0.22μm filter membrane. Then take 1.5ml of Opti-MEM and dissolve 120μl of 1mg / ml PEI (Polysciences, #23966-2) and let it stand for 5 minutes. Slowly add PEI to the plasmid, incubate at room temperature for 10 minutes, slowly drip the plasmid PEI mixed solution while shaking the culture flask, and culture in a 37℃ 8% CO2 shaker for 5 days. Observe cell viability after 5 days. Collect the culture, centrifuge at 3300g for 10 minutes, and take the supernatant; then centrifuge the supernatant at high speed to remove impurities. Use PBS pH7.4 buffer to equilibrate the cell suspension containing MabSelect. TM (GE Healthcare, #71-5020-91) gravity column (Bio-Rad, #7311550), 2-5 column volumes of washing. The supernatant sample was passed through the column; the column was washed with 5-10 column volumes of PBS buffer, and the target protein was eluted with 0.1M glycine at pH 3.5, and then adjusted to neutral with Tris-HCl at pH 8.0. Finally, the solution was concentrated with an ultrafiltration tube (Millipore, #UFC901024) and replaced with PBS buffer or a buffer containing other components to obtain a purified recombinant antibody solution. Finally, the purified recombinant antibody solution was purified using NanoDrop (Thermo, NanoDrop TM One) Determine the concentration, aliquot, and store for future use.
[0082] Example 3 Sequence Analysis and Optimization of Antibodies
[0083] The sequence of an antibody's heavy chain variable domain is derived from events such as rearrangement and somatic hypermutation of the germline V, D, and J gene segments of the heavy chain gene group on chromosomes; the sequence of the light chain variable domain is derived from events such as rearrangement and somatic hypermutation of the germline V and J gene segments of the light chain gene group. Gene rearrangement and somatic hypermutation are major factors in increasing antibody diversity. Antibodies derived from the same germline V gene segment may also produce different sequences, but overall similarity is high. Using algorithms such as IMGT / DomainGapAlign (http: / / imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi) or NCBI / IgBLAST (https: / / www.ncbi.nlm.nih.gov / igblast / ), the likely germline gene segments at the time of gene rearrangement can be inferred from the variable domain sequence of an antibody. The CD40 antibody sequence obtained in Example 1 was analyzed, and the germline V gene segments of its heavy chain variable domain (VH) and light chain variable domain (VL) are listed in Table 2.
[0084] Protein or polypeptide amino acid chain sometimes introduces chemical modification after translation synthesis in cell, is called post-translational modification (PTM).If there is PTM in the variable domain of antibody, especially antigen binding region (such as CDR), the existence of these PTMs is likely to have a larger impact on the combination of antigen, and may also bring changes to the physicochemical properties of antibody.For example, glycosylation, deamidation, isomerization, oxidation etc. may all increase the instability or heterogeneity of antibody molecules, thereby increasing the difficulty and risk of antibody development.Thereby avoiding some potential PTMs for the development of therapeutic antibodies is very important.Along with the accumulation of experience, people find that some PTMs are highly correlated with the composition of amino acid sequence, especially the " pattern " of adjacent amino acids, so that potential PTMs can be predicted from the primary amino acid sequence of protein.Table 2 has listed the PTMs (NS may be deamidation sites) of the variable domain VH and VL prediction of the antibody of embodiment 1.
[0085] Amino acid mutations can be used to disrupt the amino acid sequence pattern of a PTM, thereby reducing or eliminating the formation of a specific PTM. Different mutation design methods are used depending on the antibody sequence and the PTM sequence pattern. One method is to replace the "hotspot" amino acid (such as N or S in the NS pattern) with an amino acid with similar physicochemical properties (such as mutating N to Q). If the PTM sequence pattern originates from a high-frequency somatic mutation and does not exist in the germline gene sequence, another approach can be to replace the sequence pattern with the corresponding germline gene sequence. In practice, multiple mutation design methods may be used for the same PTM sequence pattern.
[0086] Table 3 lists the new antibody molecules obtained by amino acid mutation of antibody PR003379.
[0087] Table 4 lists the sequences of the CD40 antibodies in the present application and the amino acid sequences of the CDRs defined according to the Chothia definition rules. These CD40 antibodies include a positive control antibody, the CD40 antibody PR003379 of the present invention, and mutant molecules thereof.
[0088] Table 2: Germline gene analysis and PTM site analysis of CD40 antibodies
[0089] Table 3: Mutation site design of PR003379 of CD40 antibody
[0090] Table 4: Sequence numbering table of CD40 antibody sequences and CDR sequences (Chothia) in the present invention application
[0091] Example 4 Binding to CD40-Expressing Cells
[0092] This example is to investigate the binding activity of CD40-targeting antibodies to cells expressing CD40.
[0093] Flow cytometry (FACS) was used to detect the binding ability of CD40 antibodies to cells such as CHO-K1 / hCD40 (produced by Beijing Kangyuan Broadcom) that highly expresses human CD40, CHO-K1 / cyCD40 (produced by Beijing Kangyuan Broadcom) that highly expresses cynomolgus macaque CD40, and lymphoma cells Raji (ATCC, #CCL-86) that highly express human CD40. Specifically, cells were digested and resuspended in complete culture medium (F-12K for CHO-K1 cells and RPMI-1640 for Raji cells); the cell density was adjusted to 1×10 6 Cells / mL. 100 μL cells / well were seeded in a 96-well V-bottom plate (Corning, #3894), followed by adding 100 μL / well of the antigen-binding protein to be tested at 2 times the final concentration and mixing evenly. The highest final concentration of the antigen-binding protein was 300 nM, with a total of 8 concentrations, 5-fold concentration gradient dilution, and hIgG (Crownbio, #C0002) as a negative control. The positive control molecules are the molecules in Table 1-5. The cells were placed at 4°C and incubated in the dark for 1 hour. Afterwards, 100 μL / well of pre-cooled PBS was added to rinse the cells twice, centrifuged at 500g, 4°C for 5 minutes, and the supernatant was discarded. Then 100 μL / well of fluorescent secondary antibody (goat anti-human IgG (H+L) secondary antibody, Alexa 488 conjugate, Invitrogen, #A11013, 1:1000 dilution) and incubate at 4°C in the dark for 30 minutes. Wash cells twice with 200 μL / well of pre-cold PBS, centrifuge at 500g for 5 minutes at 4°C, and discard the supernatant. Finally, resuspend cells in 200 μL / well of pre-cold PBS. Fluorescence and luminescence signals were read using a BD FACS CANTO II flow cytometer or an ACEA NovoCyte flow cytometer, and data were processed and analyzed using FlowJo v10 software (FlowJo, LLC).
[0094] GraphPad Prism 8 software was used for data processing and graphical analysis. The binding curve of the antibody to the target cells and parameters such as the EC50 value were obtained through four-parameter nonlinear fitting.
[0095] Example 4.1 Binding to human CD40 cells CHO-K1 / hCD40
[0096] Figures 1A, 1B, 1C, and 1D, as well as Table 5, show the binding activity of the CD40 antibody PR003379 and its variants to CHO-K1 / hCD40. The results showed that PR003379 and its variants had excellent binding activity to human CD40; furthermore, PR003379 exhibited stronger binding activity than control molecules, for example, with an EC50 superior to that of selicrelumab and CDX-1140, and a maximum MFI higher than that of APX005 and CDX-1140.
[0097] Table 5: Binding of PR003379 and its variants to CHO-K1 / hCD40 (corresponding to Figures 1A-1D)
[0098] Example 4.2 Binding to human CD40 cells Raji
[0099] Figures 2A, 2B, 2C, 2D, and 2E and Table 6 show the binding activity of CD40 antibody PR003379 and its variant molecules to Raji cells. The results showed that PR003379 and its variant molecules could strongly bind to Raji cells; moreover, the binding activity of PR003379 was stronger than that of the control molecule.
[0100] Table 6: Binding of PR003379 and its variants to Raji cells (corresponding to Figures 2A-2E)
[0101] Example 4.3 Binding to Cynomolgus Monkey CD40 Cells CHO-K1 / cyCD40
[0102] Figures 3A, 3B, 3C, and 3D, as well as Table 7, show the binding activity of the CD40 antibody PR003379 and its variants to cynomolgus monkey CD40 cells (CHO-K1 / cyCD40). The results showed that PR003379 and its variants had excellent binding activity to cynomolgus monkey CD40; moreover, the binding activity of PR003379 was stronger than that of the control molecule.
[0103] Table 7: Binding of PR003379 and its variants to CHO-K1 / cyCD40 (corresponding to Figures 3A-3D)
[0104] Example 5 Affinity for CD40 protein
[0105] To detect the affinity of CD40 antibody to antigen, such as human CD40 protein, the binding kinetics between antigen and antibody were analyzed by biofilm interferometry (BLI) technique using Octet Red 96e (Fortebio) molecular interaction analyzer.
[0106] 10× Kinetic Buffer (ForteBio, #18-1105) was diluted to 1× for affinity testing and dilution of antigens and antibodies. When measuring the affinity of antigens and antibodies, the sensor was rotated at 1000 rpm. First, an AHC sensor (Fortebio, #18-5060) placed in a column was equilibrated in the above-mentioned test buffer diluted to 1× for 10 minutes. The CD40 antibody was then captured using the AHC sensor with a capture height of 0.85 nm. After the AHC sensor was equilibrated in the buffer for 120 seconds, it was combined with a 2-fold serial dilution of human CD40 protein (the concentration range of CD40 bound to PR003379 and CDX-1140 was 20-5 nM and 0 nM; the concentration range of CD40 bound to APX005M and Selicrelumab was 120-30 nM and 0 nM) for 180 seconds, followed by dissociation for 500 seconds. Finally, the AHC sensor was immersed in a 10 mM glycine-hydrochloric acid solution, pH 1.5, for regeneration to elute the protein bound to the sensor.
[0107] When performing data analysis using Octet Data Analysis software (Fortebio, version 11.0), 0 nM was used as the reference well, the reference signal was subtracted (reference subtraction), and the "1:1 Global fitting" method was selected for data fitting to calculate the kinetic parameters of antigen-CD40 antibody binding, and the kon (1 / Ms) value, kdis (1 / s) value, and KD (M) value were obtained.
[0108] The affinity test results are shown in Table 8. PR003379 binds to human CD40 protein with strong affinity (about 138 pM), which is stronger than that of the positive control antibody.
[0109] Table 8: Affinity of CD40 Antibodies Binding to Human CD40 Protein
[0110] Example 6 Activity in Fluorescent Reporter Gene Assay
[0111] This example uses a fluorescent reporter gene assay to investigate the effects of CD40 antibody on CD40 activation with and without Fc crosslinking. Fc-mediated crosslinking of the antibody was performed using cells that overexpress human CD32B to investigate whether crosslinking could further enhance CD40 activation.
[0112] CHO-K1 cells expressing human CD32B (CHO-K1 / hCD32B (Genscript, #M00600) and CHO-K1 cells were cultured at 1×10 4 / hole 1×10 4 / well, 100 μL / well was plated into a 96-well plate (PerkinElmer, #6005181), and incubated overnight at 37°C in a 5% CO2 environment. The supernatant was removed, and HEK293-hCD40-NFkB reporter gene cells expressing human CD40 and NFkB-luciferase reporter genes (BPS bioscience, #60626) were collected and plated at 5×10 4 / well, add 50 μL / well to a 96-well plate. Add 50 μL / well of the test antibody protein dilution, starting at 100 nM, and dilute 5-fold, for a total of 8 concentrations. Incubate at 37°C in a 5% CO2 environment for 6 hours. Add ONE-Glo TM Luciferase reagent (Promega, #E6110) was incubated at room temperature for 5 minutes, and luminescence was measured using a microplate reader (PerkinElmer EnSpire). Data processing and graphical analysis were performed using GraphPad Prism 8 software. Four-parameter nonlinear fitting was used to generate curves showing the relative fluorescence units (RLU) and EC50 values associated with antibody concentration. Samples incubated with CD40 antibody and CHO-K1 / hCD32B cells are referred to as "crosslinked." Samples incubated with CD40 antibody and CHO-K1 cells are not crosslinked.
[0113] As shown in Figures 4A, 4B, 4C, and 4D and Table 9, PR003379 and the control antibody APX005M have a very obvious "cross-linking enhancement" effect, that is, under the condition of CD32B-mediated antibody cross-linking, PR003379 and APX005M can significantly amplify the signal of the fluorescent reporter gene, indicating that the activation effect on the downstream signaling molecules of the CD40 molecule is significantly enhanced.
[0114] Figures 5A and 5B and Table 10 show the fluorescence intensity enhancement fold of PR003379 variants on reporter cell activation with or without CD32B cell-mediated cross-linking. The results indicate that PR003379 variants significantly enhance CD40 molecule activation under cross-linking conditions, as evidenced by a significant decrease in their EC50 values under cross-linking conditions compared to those without cross-linking (represented as "fold (uncross-linked EC50 / cross-linked EC50)" > 1).
[0115] From Tables 9 and 10, the RLU multiples / folds represent the difference in activation potential of the antibody under two conditions, or the therapeutic window, reflecting that the multiples of PR003379 and its derivative antibodies are better than those of existing antibodies and have a larger therapeutic window.
[0116] Table 9: Activity of CD40 Antibodies in Activating HEK293-CD40-NFkB Reporter Cells
[0117] Table 10: PR003379 variants activate reporter gene cell activity under cross-linked and non-cross-linked conditions
[0118] Example 7 Activity in DC cell activation assay
[0119] In this example, cells highly expressing human CD32B were used to perform Fc-mediated cross-linking of antibodies to investigate whether cross-linking could further enhance the ability of CD40 antibodies to activate DC cells.
[0120] CHO-K1 cells expressing human CD32B, CHO-K1 / hCD32B and CHO-K1 cells were cultured at 1×10 4 / well, 50 μL / well was plated into a 96-well plate (Corning, #3599). 50 μL / well of the test antibody protein dilution was added, with a starting concentration of 100 nM and 5-fold dilution for a total of 8 concentrations. 2×10 induced mature DC cells isolated from human PBMC were added. 4The cells were incubated at 37°C, 5% CO2, with 100 μL / well. The supernatants were collected on the second day and assayed for IL-12p40 using a human IL-12p40 ELISA kit (R&D system, #DY240). Data were processed and analyzed using GraphPad Prism 8. A four-parameter nonlinear fit was used to generate the curves for antibody concentration-dependent IL-12p40 release and the EC50 value. Samples incubated with CD40 antibody and CHO-K1 / hCD32 B cells were designated "crosslinked." Samples incubated with CD40 antibody and CHO-K1 cells were not crosslinked.
[0121] The results are shown in Figures 6A, 6B, 6C, and 6D and Table 11. PR003379 has a very obvious "cross-linking enhancement" effect, that is, in the absence of CD32B-mediated antibody cross-linking, the level of IL-12p40 released by PR003379-activated DC cells is limited; however, in the presence of CD32B-mediated antibody cross-linking, PR003379 can significantly enhance the activation of DC cells, and the maximum value of IL-12p40 can reach 1243.0 pg / mL, far exceeding that of other control antibodies.
[0122] Table 11: CD40 antibody activates DC cells to release cytokine IL-12p40
[0123] Example 8 Blocking the Binding of CD40 and CD40L
[0124] To detect the effect of CD40 antibody on the binding of CD40 and CD40L, CHO-K1 / hCD40 cells were cultured at 2×10 5 100 μL / well was plated into a 96-well plate (Corning, #3799). The supernatant was centrifuged and the test antigen-binding protein dilution was added at 50 μL / well. The starting concentration was 500 nM and the cells were diluted 5-fold to a total of 8 concentrations. 20 μg / mL human CD40L-his protein (Sino Biological, #10239-H08E) was added at 50 μL / well and incubated at 4°C for 1 hour. The cells were washed three times with FACS buffer (1xPBS with 2% FBS). A 1:400 dilution of an anti-histidine tag secondary antibody (GenScript, #A01800) was added and incubated at 4°C for 1 hour. The cells were washed twice with FACS buffer and resuspended in ice-cold PBS. Fluorescence signals were read using a BD FACS CANTO II flow cytometer or an ACEA NovoCyte flow cytometer, and data were processed and analyzed using FlowJo v10 software (FlowJo, LLC).
[0125] GraphPad Prism 8 software was used for data processing and graphical analysis. The antibody concentration-dependent inhibition rate curve and IC50 value were obtained through four-parameter nonlinear fitting.
[0126] As shown in FIG7 and Table 12, PR003379 exhibited partial inhibition of the binding between CD40 and CD40L, with the maximum inhibition rate being 41.9%.
[0127] Table 12: CD40 antibodies inhibit the binding of CD40 and CD40L
[0128] Example 9: Determination of Epitope Competition of Antibodies Binding to CD40 Using BLI Method
[0129] To detect the binding epitopes of CD40 antibodies, epitope competition experiments were performed on the CD40 antibodies selicrelumab, APX005M, and PR003379 using BLI technology using the Octet Red 96e (Fortebio) Molecular Interaction Analyzer. Step 1: Acquire 100% signal for the antibody: The CD40 protein (Sino Biological, #10774-H08H) was captured using a HIS1K sensor (Fortebio, #18-5120) at a capture height of 0.2 nm. The sensor was equilibrated in buffer for 120 seconds and then immersed in each antibody diluted to 140 nM for 220 seconds. The final signal resulting from antibody-CD40 binding was recorded as the 100% signal for that antibody. Step 2: Epitope competition: The CD40 protein was captured using a HIS1K sensor at a capture height of 0.2 nm. The sensor was immersed in the primary antibody (concentration of 140 nM) for 220 seconds. The HIS1K sensor was then immersed in a mixture of the primary and secondary antibodies (final concentration of both antibodies was 140 nM) for 220 seconds. The difference in signal after immersing the sensor in the antibody mixture was recorded as the signal of the antibody as the secondary antibody. The inhibition rate was calculated using the following formula: Inhibition rate (%) = (A–B) / A*100
[0130] A: 100% signal of a certain antibody (obtained from the first step), B: signal of the antibody as a secondary antibody (obtained from the second step).
[0131] If the inhibition rate obtained is greater than 80%, it means that the epitopes of the two antibodies almost completely overlap; if the inhibition rate is greater than 40% and less than 80%, it means that the epitopes bound by the two antibodies do not completely overlap or the epitopes are very similar; if the inhibition rate is less than 40%, it means that the epitopes of the two antibodies are different.
[0132] The results are shown in Table 13. The binding epitopes of PR003379 and Selicrelumab are almost identical, but different from the epitope of APX005M.
[0133] Table 13: BLI epitope competition assay
[0134] Example 10 Anti-tumor activity in the MC38-hPD-L1 / hCD40-C57BL / 6J mouse model and effect on mouse body weight
[0135] To test the anti-tumor activity of CD40 antibodies in vivo, MC38 mouse colon cancer cells overexpressing human PD-L1 (MC38 / hPD-L1, provided by Shanghai Southern Model Organisms Co., Ltd.) were cultured in a 37°C, 5% CO2 incubator in DMEM supplemented with 10% inactivated fetal bovine serum. Cells were passaged every 3 to 4 days after confluence. MC38 / hPD-L1 cells in the logarithmic growth phase were collected, resuspended in PBS, and counted. The cell concentration was adjusted to 1.0×10 7 / mL; the cell suspension was inoculated subcutaneously in the right flank of CD40 humanized transgenic mice (hCD40-C57BL / 6J, provided by Shanghai Southern Model Organisms Co., Ltd.) using a 1mL syringe, 100μL / mouse, and approximately 1.0×10 6 When the average tumor volume reaches 114 mm 3 At the same time, mice with moderate tumor volume were selected and randomly assigned to experimental groups according to tumor volume, with 6 mice in each group. Drug administration began on the day of grouping.
[0136] The results are shown in Figures 8A and 8B. On the 10th day after the start of administration, the average tumor volume of the control group IgG1 (3 mg / kg) was 1409.41±205.02 mm 3 The average tumor volumes of the selicrelumab (3 mg / kg) group, CDX-1104 (3 mg / kg) group, and PR003379 (3 mg / kg) group were 460.96±68.61 mm 3 、1345.22±162.94mm 3 、447.89±50.74mm 3 The tumor inhibition rates were 73.22%, 4.92%, and 74.24%, respectively. Throughout the experiment, the body weight gains of mice in the IgG1 control group, selicrelumab, CDX-1104, and PR003379 groups were 12.24%, 7.31%, 7.56%, and 1.86%, respectively. The mice remained in normal condition.
[0137] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. An antigen-binding protein targeting CD40, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region (VL) comprises LCDR1, LCDR2, and LCDR3, and the heavy chain variable region (VH) comprises HCDR1, HCDR2, and HCDR3; wherein: The LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:33, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:41, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:49 or variant 3 having 3, 2, or 1 amino acid mutations in SEQ ID NO:49; the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:7, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:15, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:23; Preferably, the variant 3 includes an amino acid sequence having a PTM site mutation in the amino acid sequence shown in SEQ ID NO: 49, preferably including an amino acid sequence having an amino acid mutation at position 4 and / or 5 of the amino acid sequence shown in SEQ ID NO: 49, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution.
2. The antigen binding protein targeting CD40 according to claim 1, wherein The variant 3 is an amino acid sequence as shown in any one of SEQ ID NOs: 50-73; Preferably, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:33, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:41, and the LCDR3 comprises the amino acid sequence shown in any one of SEQ ID NOs:49-73; the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:7, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:15, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:
23.
3. The CD40-targeting antigen binding protein according to claim 1 or 2, wherein: The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:85, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:85, and the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:81, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:81; preferably, the light chain variable region comprises the amino acid sequence as shown in any one of SEQ ID NOs:85-109, and the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
81.
4. The antigen binding protein targeting CD40 according to any one of claims 1 to 3, wherein The antigen binding protein targeting CD40 satisfies at least one of the following three conditions: (1) The antigen-binding protein targeting CD40 is a full-length antibody, Fab, Fab', F(ab')2 or Fv, and the Fv is preferably a scFv; (2) The antigen-binding protein targeting CD40 is a monospecific antibody, a bispecific antibody, or a multispecific antibody; (3) The antigen binding protein targeting CD40 is a monoclonal antibody or a polyclonal antibody; Preferably, the antigen binding protein targeting CD40 is a full-length antibody, which comprises a light chain and a heavy chain; the light chain includes a light chain constant region (CL), which is preferably a human antibody light chain constant region; the heavy chain includes a heavy chain constant region (CH), which is preferably a human antibody heavy chain constant region, more preferably a heavy chain constant region of the hIgG1, hIgG2, hIgG3 or hIgG4 subtype, and further preferably a heavy chain constant region of the hIgG1 subtype.
5. The antigen binding protein targeting CD40 according to any one of claims 1 to 4, characterized in that The antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain, wherein the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 114 or 115, and the light chain comprises the amino acid sequence shown in any one of SEQ ID NOs: 119-143; preferably, the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 114, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 119; or, the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 115, and the light chain comprises the amino acid sequence shown in any one of SEQ ID NOs: 119-143.
6. A chimeric antigen receptor, characterized in that The chimeric antigen receptor comprises the CD40-targeting antigen binding protein according to any one of claims 1 to 5.
7. An isolated nucleic acid, characterized in that The isolated nucleic acid encodes the CD40-targeting antigen binding protein according to any one of claims 1 to 5 or the chimeric antigen receptor according to claim 6.
8. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the isolated nucleic acid according to claim 7; preferably, the recombinant expression vector comprises a eukaryotic cell expression vector and / or a prokaryotic cell expression vector.
9. A transformant, characterized in that The transformant comprises the isolated nucleic acid according to claim 7 or the recombinant expression vector according to claim 8; preferably, the host cell of the transformant is a prokaryotic cell and / or a eukaryotic cell, the prokaryotic cell is preferably an E. coli cell such as TG1, BL21, and the eukaryotic cell is preferably a HEK293 cell or a CHO cell.
10. A method for preparing the CD40-targeting antigen binding protein according to any one of claims 1 to 5, comprising the following steps: The transformant according to claim 9 is cultured, and the antigen-binding protein targeting CD40 is obtained from the culture.
11. An antibody-drug conjugate, characterized in that: The antibody-drug conjugate comprises the CD40-targeting antigen binding protein according to any one of claims 1 to 5 and a cytotoxic agent or a label; preferably, the cytotoxic agent is MMAF or MMAE, and the label is a fluorescent agent.
12. A genetically modified cell, characterized in that The genetically modified cells express the chimeric antigen receptor as described in claim 6; preferably, the genetically modified cells are eukaryotic cells, preferably isolated human cells, and more preferably immune cells such as T cells or NK cells.
13. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises one or more of the CD40-targeting antigen binding protein according to any one of claims 1 to 5, the isolated nucleic acid according to claim 7, the recombinant expression vector according to claim 8, the antibody-drug conjugate according to claim 11, and the genetically modified cell according to claim 12, and a pharmaceutically acceptable carrier and / or a pharmaceutically acceptable adjuvant; preferably, the pharmaceutical composition further comprises other anti-tumor antibodies as active ingredients.
14. A detection reagent, characterized in that The detection reagent comprises the CD40-targeting antigen-binding protein according to any one of claims 1 to 5 and / or the antibody-drug conjugate according to claim 11; preferably, the detection reagent is in liquid dosage form, gaseous dosage form, solid dosage form, and semisolid dosage form; more preferably, the detection reagent further comprises a secondary antibody, CD40 or a derivative thereof, the secondary antibody being, for example, an anti-human IgG antibody conjugated to horseradish peroxidase and an anti-human IgG antibody conjugated to biotin.
15. A medicine kit, characterized in that: The kit comprises kit A, which contains one or more of the antigen binding protein targeting CD40 according to any one of claims 1 to 5, the pharmaceutical composition according to claim 13, the detection reagent according to claim 14, the antibody-drug conjugate according to claim 11, and the genetically modified cell according to claim 12; Preferably, the kit further comprises a kit B, which contains other anti-tumor antibodies or pharmaceutical compositions comprising the other anti-tumor antibodies, and / or one or more of a group consisting of hormone preparations, targeted small molecule preparations, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, and vaccines.
16. Use of one or more of the CD40-targeting antigen-binding protein according to any one of claims 1 to 5, the isolated nucleic acid according to claim 7, the recombinant expression vector according to claim 8, the pharmaceutical composition according to claim 13, the detection reagent according to claim 14, the kit according to claim 15, the antibody-drug conjugate according to claim 11, and the genetically modified cell according to claim 12 in the preparation of a medicament for diagnosing, preventing, and / or treating tumors; preferably, the tumors include solid tumors and hematological tumors; more preferably, the tumors include B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal carcinoma, malignant melanoma, pancreatic cancer, and colon cancer.
17. A method for detecting CD40 in a sample, characterized in that: The method comprises the step of contacting the sample with the CD40-targeting antigen binding protein according to any one of claims 1 to 5, the detection reagent according to claim 14, and / or the antibody-drug conjugate according to claim 11; preferably, the method is for non-diagnostic and / or therapeutic purposes.
18. A method for diagnosing, treating, and / or preventing tumors, comprising administering to a patient in need thereof a therapeutically effective amount of one or more of the CD40-targeting antigen binding protein according to any one of claims 1 to 5, the isolated nucleic acid according to claim 7, the recombinant expression vector according to claim 8, the pharmaceutical composition according to claim 13, the detection reagent according to claim 14, the kit according to claim 15, the antibody-drug conjugate according to claim 11, and the genetically modified cell according to claim 12, or using the kit according to claim 15 to diagnose or treat a patient in need thereof. Preferably, the tumor comprises a solid tumor and a hematological tumor. More preferably, the tumor comprises B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal carcinoma, malignant melanoma, pancreatic cancer, and colon cancer.
Citation Information
Patent Citations
Anti-CD40 antibodies and methods of use
CN104918957A
Anti-CD40 antibody and application thereof
CN109678959A
Anti-CD40 antibodies and uses thereof
WO2020253722A1
